ICU Medical (NASDAQ:ICUI) Issues Quarterly Earnings Results

ICU Medical (NASDAQ:ICUI - Get Free Report) posted its quarterly earnings data on Thursday. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.48 by $0.24, Zacks reports. The firm had revenue of $629.81 million for the quarter, compared to the consensus estimate of $599.10 million. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. ICU Medical updated its FY 2025 guidance to 6.550-7.250 EPS.

ICU Medical Stock Down 3.3 %

Shares of ICU Medical stock traded down $4.77 on Monday, hitting $141.56. 373,294 shares of the company traded hands, compared to its average volume of 213,030. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. ICU Medical has a 12-month low of $93.36 and a 12-month high of $196.26. The company has a 50-day moving average price of $160.42 and a 200 day moving average price of $166.32. The company has a market cap of $3.47 billion, a PE ratio of -30.98 and a beta of 0.63.

Insider Activity at ICU Medical

In other news, CEO Vivek Jain sold 1,373 shares of ICU Medical stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at $16,262,119.64. The trade was a 1.30 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.70% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ICUI shares. KeyCorp upped their price target on shares of ICU Medical from $198.00 to $209.00 and gave the company an "overweight" rating in a research report on Wednesday, November 13th. Jefferies Financial Group raised ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 target price for the company in a research report on Wednesday, December 11th. Needham & Company LLC reissued a "hold" rating on shares of ICU Medical in a research report on Wednesday, November 13th. Finally, StockNews.com raised ICU Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $199.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.